Circular Genomics’ Post

Auvelity is making a difference for people with major depressive disorder and this could be a game-changer for people struggling with depression. It's the first rapid-acting oral medication that works as an NMDA receptor antagonist, which is completely different from the usual antidepressants that have been around for more than 60 years. What’s amazing is how quickly it seems to work—people are seeing improvements in their symptoms as early as the first week, and some even reach remission by the second week. The graph clearly shows the steady rise in prescriptions since its launch, which means doctors and patients are really seeing the benefits #MentalHealth #DepressionTreatment #Antidepressants #Auvelity

People with alcohol use disorder, and particularly women, are at increased risk of depressive disorders. However, research is still inconclusive on the underlying mechanisms and on the best treatment approach for individuals with both disorders.   Read this ARCR review—one of our most-cited articles for 2024, according to Web of Science—to learn more about the complex relationship between alcohol use disorder and depressive disorders: https://go.nih.gov/dzYXapk. (Authors: R. Kathryn McHugh and Roger D. Weiss) #alcoholresearch #arcrjournal #depressionawareness

How soon is now? Patients with major depressive disorder are candidates for treatment with a rapid-acting antidepressant. Learn more with this case study: http://ms.spr.ly/6048l5YWm

#ButterflyBytes | Thyroid disorders have been dismissed by many. The fact is, it has the ability to wreak havoc on the person suffering from it. From being unable to remember things to severe body aches, it snatches away the normal self from the sufferer. Here's wishing that more people would speak up about the struggles they face and not dismiss these symptoms as a figment of imagination. If you are struggling with a thyroid disorder, please feel free to comment below the post using the #thyroidstrugglesarereal. Let's build a circle of #compassion ... #thyroid #thyroidawareness #thyroidproblems #circleofcompassion

🧠 Parkinson’s disease can affect the brain in ways that cause modest personality changes over time. Also, PD medication can, in some instances, cause impulse control disorders (ICD). Read more about Parkinson’s effect on personality and what to expect along with tips and thoughts on treating other possible non-motor symptoms like depression. https://lnkd.in/e33pxfU7 #NonMotorSymptoms #Depression #Parkinsons #ImpulseControl #Personality

🌟 Can Substance Use Disorder (SUD) Be Treated Successfully? Absolutely! 🌟 Yes, SUD is a treatable disorder! 🚀 Thanks to extensive research on SUD and its treatment, we now have effective, research-based methods that help individuals stop using substances and lead productive, fulfilling lives. This journey is often referred to as being in recovery. 💪 🔍 Can SUD Be Cured? 🔍 While SUD treatment is not a cure, it is very much like managing other chronic diseases such as diabetes or asthma. It helps people counteract the disruptive effects of SUD on their brain and behavior, allowing them to regain control of their lives. 🌈 With the right support and treatment, recovery is possible! 🌟💖 #RecoveryIsPossible #SubstanceUseDisorder #HopeAndHealing #MentalHealthMatters #AddictionRecovery #StrongerTogether #RecoveryMonth

Migraine affects over a billion individuals worldwide annually, ranking it among the most common neurological disorders!¹ Beyond the physical pain, it often increases the risk of anxiety, depression, and even suicide.² Lundbeck Gulf raises awareness and pushes for better care that addresses both the physical and emotional toll. Watch the video to learn more and Speak Up for Migraine🌟 #LundbeckMEA #LundbeckCares #MigraineAwareness #MentalHealthMatters

PMDD can NOT be diagnosed via blood, hormone, or saliva tests. These tests CAN, however, RULE OUT any underlying disorders, including hormone imbalances or thyroid issues, which can mimic PMDD symptoms. The only way to currently test for PMDD is by tracking symptoms for a span of TWO OR MORE menstrual cycles. You must track your symptoms on a daily basis, alongside your menstrual cycle. We offer a free printable tracker and a free tracking app for your smartphone at https://lnkd.in/ebDMCBvn. If you are having issues gaining a diagnosis, check out https://lnkd.in/eJqNAwrV. Want to learn more about the premenstrual exacerbation/worsening of the symptoms of another disorder? Visit iapmd.org/pmdd-v-pme. Have a look at iapmd.org/about-pmdd for more info on PMDD itself. Remember - you deserve to feel good! #feelgoodfriday YOU'VE GOT THIS! 💙 #pmdd #pme #pms #pmddpeeps #symptoms #suicideprevention #diagnosis #move #gooutside #ocean #beach #suicide #lifeguard #trachyourcycle #suicideprevention #advocacy #mycycle #myperiod #symptoms #youarenotalone #mentalhealth #premenstrual #menstrual #premenstrualhealth  #youvegotthis #anxiety #depression #sleepissues #mood #hormones

SUD is fundamentally a brain disorder. The region of the brain that mediates reward seeking behaviors, the meso-limbic cortex, functions differently in those with SUD — for reasons not yet fully understood — as compared to those who don’t present with SUD. When people are in active addiction, the decision to misuse substances is not a conscious one. While this may seem incongruous since SUD starts with a volitional choice, the area of the brain responsible for executive decision-making (by definition volitional choices), the prefrontal cortex, is overridden by signals from the meso-limbic cortex. The key to sustainable and long-term recovery is to stop misusing substances long enough so the brain’s neural pathways can reset and reform to enable the prefrontal cortex to reassume its executive decision-making role. This seems tricky since making a decision to seek treatment is a volitional one. But it’s instructive to remember that the vast majority of people with SUD DO want to stop misusing substances but despite willpower, the urging and threats from loved ones, friends and others, and often dire consequences, find it extremely difficult to stop. Inpatient treatment can be very helpful. But the real work begins when someone with SUD returns to their old environment after treatment. This is where ARCNH comes in. Our recovery coaches help participants (those with SUD) begin to develop a long-term recovery plan to enable sustainable and durable recovery and support them in their efforts to succeed in doing so. The really good news is that we know from peer-reviewed articles and longitudinal studies that if people with SUD can maintain continuous sobriety (or mainly continuous sobriety meaning no more than a few slips without long-term returns to misusing substances) for a full year, they have an excellent chance (>90%) of establishing long-term and durable recovery. SUD is a brain disease. Long-term recovery IS possible. As difficult as it may be to do so, please remember that no one I’ve yet met wanted to become addicted to alcohol and/or other drugs. Their continued misuse of substances has nothing to do with intelligence, willpower or lack of courage. Keeping this in mind will help everyone with SUD as well as those who love and care about them since stigma and shame only serve to reinforce maladaptive behaviors and the continued misuse of substances. ARCNH offers evidence-based solutions to enable long-term recovery. Please know we’re available both in-person and virtually to help those recover from SUD. Long-term recovery is eminently possible. Please visit us at www.arcnh.org or call us at 603.554.8142. We look forward to helping those with SUD AND their families and friends recover from a disorder that afflicts 17.3% of the US population age 12 and over. Almost 50 million people not including their families and loved ones. It’s time. #endthestigma #stoptheshame #recoveryispossible #ARCNH #recoveryworks #hopeandloveistheanswer

#DYK? SSRIs are the most common first-line treatment for major depressive disorder (MDD), but response rates are only around 41%. MindLight™ can enhance treatment planning by identifying which patients are more likely to respond to SSRIs. In the EMBARC study, patients in MindLight’s “High Likelihood of Response” category were over 3 times more likely to respond compared to the “Low Likelihood of Response” group. Curious to learn more about how MindLight can help? Check out our website: https://hubs.la/Q02VyClT0 #MentalHealth #depression #SSRI #MindLight #genomics